Skip to main content
SpringerLink
Log in
Book cover

Bone Drugs in Pediatrics pp 67–80Cite as

Bisphosphonates in Osteogenesis Imperfecta

  • Chapter
  • First Online:

  • 837 Accesses

Abstract

Osteogenesis imperfecta (OI) is a genetic bone fragility disorder characterised by multiple fractures, reduced bone mass, deformity and disability. Management requires a multidisciplinary approach involving paediatrician, endocrinologist (bone and mineral physician), rehabilitation specialist, orthopaedic surgeon, dentist, physiotherapist and occupational therapist. Bisphosphonate treatment is the mainstay of medical treatment in OI and has been shown to decrease bone pain, enhance well-being and improve mobility and muscle strength, in addition to reducing the incidence of fractures. This chapter summarises the historical use, safety and efficacy of bisphosphonate therapy in children and adolescents with OI.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Russell RGG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM, Dietz AA, et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet. 1970;2(7679):899–902.

    Article  PubMed  CAS  Google Scholar 

  2. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961–78.

    Article  PubMed  CAS  Google Scholar 

  3. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581–9.

    Article  PubMed  CAS  Google Scholar 

  4. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9(5):745–51.

    Article  PubMed  CAS  Google Scholar 

  5. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228–36.

    Article  PubMed  CAS  Google Scholar 

  6. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;(4):CD005088.

    Google Scholar 

  7. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–16.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  8. Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012;91(2):343–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011;88(3):362–71.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007;40(3):638–44.

    Article  PubMed  CAS  Google Scholar 

  11. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002;31(1):12–8.

    Article  PubMed  CAS  Google Scholar 

  12. Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006;127(2):291–304.

    Article  PubMed  CAS  Google Scholar 

  13. Byers PH. Etiology of osteogenesis imperfecta: an overview of biochemical and molecular genetic analyses. Connect Tissue Res. 1995;31(4):257–9.

    Article  PubMed  CAS  Google Scholar 

  14. Ben Amor IM, Glorieux FH, Rauch F. Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos. 2011;2011:540178.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2010;86(4):551–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi M, Alrasheed S, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet. 2010;86(3):389–98.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  17. Lapunzina P, Aglan M, Temtamy S, Caparros-Martin JA, Valencia M, Leton R, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet. 2010;87(1):110–4.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Misof K, Landis WJ, Klaushofer K, Fratzl P. Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress. J Clin Invest. 1997;100(1):40–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  19. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26(6):581–9.

    Article  PubMed  CAS  Google Scholar 

  20. Sillence DO, Morley K, Ault JE. Clinical management of osteogenesis imperfecta. Connect Tissue Res. 1995;31(4):S15–21.

    Article  PubMed  CAS  Google Scholar 

  21. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16(5):360–3.

    Article  PubMed  CAS  Google Scholar 

  22. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947–52.

    Article  PubMed  CAS  Google Scholar 

  23. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr. 1998;87(1):64–8.

    Article  PubMed  CAS  Google Scholar 

  24. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85(5):1846–50.

    PubMed  CAS  Google Scholar 

  25. Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013;79(6):333–40.

    Article  PubMed  CAS  Google Scholar 

  26. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110(9):1293–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  27. Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int. 2003;72(2):103–12.

    Article  PubMed  CAS  Google Scholar 

  28. Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012;25(5–6):485–91.

    PubMed  CAS  Google Scholar 

  29. Ruck J, Dahan-Oliel N, Montpetit K, Rauch F, Fassier F. Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. J Child Orthop. 2011;5(3):217–24.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363(9419):1427–31.

    Article  PubMed  CAS  Google Scholar 

  31. Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009;24(7):1282–9.

    Article  PubMed  CAS  Google Scholar 

  32. Ward LM, Rauch F, Whyte MP, D’Astous J, Gates PE, Grogan D, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. Journal of Clinical Endocrinology & Metabolism. 2011;96(2):355–64.

    Article  CAS  Google Scholar 

  33. Bishop N, Adami S, Ahmed SF, AntÛn J, Arundel P, Burren CP, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. The Lancet. 2013;382:1424–32.

    Article  CAS  Google Scholar 

  34. Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40(4):821–7.

    Article  PubMed  CAS  Google Scholar 

  35. Biggin A, Zheng L, Briody J, McQuade M, Munns CF. Long-term effects of bisphosphonate therapy in children with osteogenesis imperfecta. Bone Abstracts. 2013;2:OP13.

    Google Scholar 

  36. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897–907.

    Article  PubMed  CAS  Google Scholar 

  37. Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94(2):400–9.

    Article  PubMed  CAS  Google Scholar 

  38. Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, et al. Circulating gammadelta T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res. 2012;27(1):227–30.

    Article  PubMed  CAS  Google Scholar 

  39. Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy. 2004;24(2):195–7.

    Article  PubMed  CAS  Google Scholar 

  40. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003;88(3):986–92.

    Article  PubMed  CAS  Google Scholar 

  41. Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004;35(1):231–4.

    Article  PubMed  CAS  Google Scholar 

  42. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111(5 Pt 1):1030–6.

    Article  PubMed  Google Scholar 

  43. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349(5):457–63.

    Article  PubMed  CAS  Google Scholar 

  44. Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res. 2004;19(7):1191–3.

    Article  PubMed  Google Scholar 

  45. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19(11):1779–86.

    Article  PubMed  CAS  Google Scholar 

  46. Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008;37(4):196–200.

    Article  PubMed  CAS  Google Scholar 

  47. Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49(1):103–10.

    Article  PubMed  CAS  Google Scholar 

  48. Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004;19(10):1742–5.

    Article  PubMed  Google Scholar 

  49. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86(5):356–64.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to acknowledge the support of the Sydney Medical School Foundation.

Author information

Authors and Affiliations

  1. Institute of Endocrinology and Diabetes, University of Sydney, The Children’s Hospital at Westmead, Westmead, NSW, Australia

    Andrew Biggin B.Sc., Ph.D., M.B.B.S. & Craig F. Munns M.B.B.S., Ph.D., F.R.A.C.P.

Authors
  1. Andrew Biggin B.Sc., Ph.D., M.B.B.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig F. Munns M.B.B.S., Ph.D., F.R.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig F. Munns M.B.B.S., Ph.D., F.R.A.C.P. .

Editor information

Editors and Affiliations

  1. Department of Orthopaedic Surgery, University of Texas Medical Branch, Galveston, Texas, USA

    Gordon L. Klein

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Biggin, A., Munns, C.F. (2014). Bisphosphonates in Osteogenesis Imperfecta. In: Klein, G. (eds) Bone Drugs in Pediatrics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7436-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-7436-5_5

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-7435-8

  • Online ISBN: 978-1-4899-7436-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation